BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology 

Regentis Biomaterials (NYSE American: RGNT) announced that the Japan Patent Office has issued a Notice of Allowance for a patent covering its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC(R), the company’s regenerative treatment for articular cartilage injuries. Regentis said the allowance expands its global intellectual property portfolio as it advances GelrinC commercialization in Europe, continues enrollment in its pivotal U.S. clinical trial and evaluates expansion into additional international markets.

The allowed patent covers proprietary protein-polymer conjugate compositions and manufacturing methods designed to eliminate the use of organic solvents while enabling stable liquid formulations. According to the company, the technology improves manufacturing efficiency, increases production yield, simplifies manufacturing and enhances scalability for commercial production. Regentis said the patent also strengthens its position in Japan, one of the world’s largest cartilage repair markets, where demand is expected to grow as the population ages and the prevalence of knee osteoarthritis increases.

To view the full press release, visit https://ibn.fm/E48Tb

About Regentis Biomaterials

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

“This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.”

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN